Unknown

Dataset Information

0

GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice.


ABSTRACT:

Introduction

Optimal glycaemia can reduce type 2 diabetes (T2D) complications. Observing retrospective continuous glucose monitoring (r-CGM) patterns may prompt therapeutic changes but evidence for r-CGM use in T2D is limited. We describe the protocol for a randomised controlled trial (RCT) examining intermittent r-CGM use (up to 14 days every three months) in T2D in general practice (GP).

Methods and analysis

General Practice Optimising Structured MOnitoring To achieve Improved Clinical Outcomes is a two-arm RCT asking 'does intermittent r-CGM in adults with T2D in primary care improve HbA1c?'

Primary outcome

Absolute difference in mean HbA1c at 12?months follow-up between intervention and control arms.

Secondary outcomes

(a) r-CGM per cent time in target (4-10?mmol/L) range, at baseline and 12 months; (b) diabetes-specific distress (Problem Areas in Diabetes).

Eligibility

Aged 18-80 years, T2D for ?1?year, a (past month) HbA1c>5.5?mmol/mol (0.5%) above their individualised target while prescribed at least two non-insulin hypoglycaemic therapies and/or insulin (therapy stable for the last four?months). Our general glycaemic target is 53?mmol/mol (7%) (patients with a history of severe hypoglycaemia or a recorded diagnosis of hypoglycaemia unawareness will have a target of 64?mmol/mol (8%)).Our trial compares r-CGM use and usual care. The r-CGM report summarising daily glucose patterns will be reviewed by GP and patient and inform treatment decisions. Participants in both arms are provided with 1?hour education by a specialist diabetes nurse.The sample (n=150/arm) has 80% power to detect a mean HbA1c difference of 5.5?mmol/mol (0.5%) with an SD of 14.2 (1.3%) and alpha of 0.05 (allowing for 10% clinic and 20% patient attrition).

Ethics and dissemination

University of Melbourne Human Ethics Sub-Committee (ID 1647151.1). Dissemination will be in peer-reviewed journals, conferences and a plain-language summary for participants.

Trial registration number

>ACTRN12616001372471; Pre-results.

SUBMITTER: Furler J 

PROVIDER: S-EPMC6059310 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice.

Furler John J   O'Neal David Norman DN   Speight Jane J   Blackberry Irene I   Manski-Nankervis Jo-Anne JA   Thuraisingam Sharmala S   de La Rue Katie K   Ginnivan Louise L   Browne Jessica Lea JL   Holmes-Truscott Elizabeth E   Khunti Kamlesh K   Dalziel Kim K   Chiang Jason J   Audehm Ralph R   Kennedy Mark M   Clark Malcolm M   Jenkins Alicia Josephine AJ   Liew Danny D   Clarke Philip P   Best James J  

BMJ open 20180717 7


<h4>Introduction</h4>Optimal glycaemia can reduce type 2 diabetes (T2D) complications. Observing retrospective continuous glucose monitoring (r-CGM) patterns may prompt therapeutic changes but evidence for r-CGM use in T2D is limited. We describe the protocol for a randomised controlled trial (RCT) examining intermittent r-CGM use (up to 14 days every three months) in T2D in general practice (GP).<h4>Methods and analysis</h4>General Practice Optimising Structured MOnitoring To achieve Improved C  ...[more]

Similar Datasets

| S-EPMC7003418 | biostudies-literature
| S-EPMC6128980 | biostudies-literature
| S-EPMC7158044 | biostudies-literature
| S-EPMC4645797 | biostudies-literature
| S-EPMC8115799 | biostudies-literature
| S-EPMC2797966 | biostudies-literature
| S-EPMC6835174 | biostudies-literature
| S-EPMC8587472 | biostudies-literature
| S-EPMC7692835 | biostudies-literature
| S-EPMC5722080 | biostudies-literature